Treatment and outcome
| All patients (n=590) | SR (n=536) | Paroxysmal AF (n=23) | Persistent AF (n=31) | P value | |
| Treatment on admission | |||||
| Anticoagulation | 525 (89.0%) | 481 (89.7%) | 19 (82.6%) | 25 (80.6%) | 0.18 |
| Warfarin | 490 (83.1%) | 451 (84.1%) | 17 (73.9%) | 22 (71.0%) | 0.08 |
| NOAC | 35 (5.9%) | 30 (5.6%) | 2 (8.7%) | 3 (9.7%) | 0.55 |
| INR at the time of hospital discharge | 2.52 (1.88–3.20) | 2.34 (2.07–2.89) | 2.38 (1.90–3.24) | 2.54 (2.13–3.29) | 0.69 |
| INR at the time of readmission (n=52) | 2.49±0.69 | 2.51±0.68 | 2.40±0.47 | 2.36±0.97 | 0.85 |
| Thrombolytic | 54 (9.2%) | 49 (9.1%) | 2 (8.3%) | 3 (9.7%) | 0.99 |
| Inferior vena cava filter | 62 (10.5%) | 59 (11.0%) | 2 (8.7%) | 1 (3.2%) | 0.37 |
| Antiplatelet | 67 (11.4%) | 40 (7.5%) | 12 (52.2%)*** | 15 (48.4%)*** | <0.001 |
| Statins | 116 (19.7%) | 90 (16.8%) | 12 (52.2%)*** | 14 (45.2%)*** | <0.001 |
| β-blocker | 91 (15.4%) | 67 (12.5%) | 9 (39.1%)** | 15 (48.4%)*** | <0.001 |
| Endotracheal intubation | 34 (5.8%) | 32 (6.0%) | 0 (0.0%) | 2 (6.5%) | 0.49 |
| Outcome | |||||
| In-hospital mortality | 54 (7.7%) | 44 (7.5%) | 3 (11.5%) | 7 (18.4%)** | 0.021 |
| 30-day mortality | 23 (3.9%) | 14 (2.6%) | 3 (12.5%)** | 6 (19.4%)*** | <0.001 |
| 6-month mortality | 84 (14.2%) | 60 (11.2%) | 9 (39.1%)*** | 15 (48.4%)**** | <0.001 |
*, **, ***: AF group vs SR group, p<0.05, p<0.01 and p<0.001, respectively.
AF, atrial fibrillation; INR, international normalised ratio; NOAC, novel oral anticoagulant; SR, sinus rhythm.